SC19220

**SC19220** is a small molecule drug that acts as a selective antagonist of the prostaglandin E2 (PGE2) receptor EP1. It has been used in studies to investigate the role of PGE2 in various biological processes, such as neurotoxicity, osteoclastogenesis, and bladder function. SC19220 is known for its ability to inhibit RANKL-induced osteoclastogenesis and has shown potential in modulating bone resorption and inflammation. **Mechanism of Action**: SC19220 competitively antagonizes PGE2 at the EP1 receptor, which is involved in several biological pathways, including bone metabolism and inflammation. It has been studied for its effects on osteoclast formation and bone resorption, as well as its potential in managing conditions related to PGE2 overactivity.

Other names

N'-acetyl-8-chlorodibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide8-chloro-dibenz[b,f][1,4]oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide